ORLANDO, Fla., Feb. 19, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company’s fourth quarter and full year 2024 financial results will be released before market open on Thursday, February 27, 2025. LENSAR’s management will host a conference call and webcast at 8:30 am ET on Thursday, February 27, 2025 to discuss the financial results a ...

Group 1 - Robert F. Abbott has been managing family investments since 1995 and incorporated options trading in 2010, focusing on covered calls and collars with long stocks [1] - Abbott is a freelance writer with a project aimed at providing information for new and intermediate-level mutual fund investors [1] - He holds a Bachelor of Arts and a Master of Business Administration (MBA) degree [1]

         24 ALLY Robotic Laser Cataract Systems™ placed in 3Q 2024 including 11 sales in EU and Southeast Asia; Robust backlog with 24 systems pending installation as of September 30, 2024 38% Revenue growth over third quarter 2023 and 22% Recurring revenue growth in twelve-month trailing average Worldwide procedure volumes increased 29% over third quarter of 2023 Installed system base grew 20% over third quarter of 2023 ORLANDO, Fla., Nov. 07, 2024 (GLOBE NEWSWIRE) -- LENSAR®, Inc. (Nasdaq: LNSR) (“LENSA ...

ORLANDO, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company’s third quarter 2024 financial results will be released before market open on Thursday, November 7, 2024. LENSAR’s management will host a conference call and webcast at 8:30 am ET on Thursday, November 7, 2024 to discuss the financial results and recent corpora ...

ORLANDO, Fla., Oct. 01, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 875 shares of the Company's common stock. The options were granted as of October 1, 2024, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Li ...

Revenue and Financial Performance - Total revenue for Q2 2024 was $12.636 million, a 5.2% increase from $12.012 million in Q2 2023[13] - Product revenue for Q2 2024 was $9.534 million, a 1.7% increase from $9.377 million in Q2 2023[13] - Lease revenue for Q2 2024 was $1.952 million, a 15.4% increase from $1.691 million in Q2 2023[13] - Service revenue for Q2 2024 was $1.150 million, a 21.8% increase from $944,000 in Q2 2023[13] - Total product and service revenue for Q2 2024 was $10,684 thousand, with the U.S. contributing $7,679 thousand[38] - Total product and service revenue for the first six months of 2024 was $19,325 thousand, compared to $16,944 thousand in the same period in 2023[38] - Lease revenue for the six months ended June 30, 2024, was $3,899 thousand, up from $3,320 thousand in the same period in 2023[56] - Revenue from products for the three months ended June 30, 2024, was $3 million, compared to $0 in the same period in 2023[82] Net Loss and Expenses - Net loss for Q2 2024 was $9.048 million, compared to $8.753 million in Q2 2023[13] - Net loss for June 2024 was $11.2 million, compared to $13.025 million in June 2023, showing a reduction in losses[17] - Net loss attributable to common stockholders for the three months ended June 30, 2024, was $9.043 million, compared to $8.753 million in the same period in 2023[85] - Basic and diluted net loss per share for the three months ended June 30, 2024, was $0.79, compared to $0.81 in the same period in 2023[85] - Total cost of revenue for Q2 2024 was $5.823 million, an 11.0% increase from $5.251 million in Q2 2023[13] - Selling, general and administrative expenses for Q2 2024 were $6.784 million, a 13.6% decrease from $7.854 million in Q2 2023[13] - Research and development expenses for Q2 2024 were $1.348 million, a 10.1% decrease from $1.499 million in Q2 2023[13] - Intangible assets impairment for Q2 2024 was $3.729 million, compared to $0 in Q2 2023[13] - The Company recorded an impairment of intangible assets of $3,943 thousand related to the phacoemulsification component in the ALLY System[56] - Amortization expense for the six months ended June 30, 2024, was $506 thousand, compared to $551 thousand in the same period in 2023[57] Cash Flow and Liquidity - Cash and cash equivalents decreased to $8.287 million as of June 30, 2024, from $20.621 million as of December 31, 2023[14] - Net cash used in operating activities for June 2024 was $9.085 million, slightly higher than $8.84 million in June 2023[17] - Purchase of investments in June 2024 amounted to $6.115 million, with no such activity in June 2023[17] - Proceeds from issuance of redeemable convertible preferred stock in June 2023 were $14.035 million, with no such activity in June 2024[17] - Cash paid for taxes in the first six months of 2024 was $22,000, compared to $18,000 in the same period of 2023[18] - Cash, cash equivalents, and investments totaled $15.4 million as of June 30, 2024, primarily held in interest-bearing accounts, money market funds, and U.S. treasury bills[142] Balance Sheet and Equity - Accumulated deficit increased to $123.091 million as of June 30, 2024, from $114.048 million at the end of March 2024[19] - Total stockholders' equity decreased to $23.645 million as of June 30, 2024, from $31.835 million at the end of March 2024[19] - The company's accumulated deficit as of June 30, 2024, is $123,091 thousand[22] - Accounts receivable, net, as of June 30, 2024, was $5,893 thousand, up from $4,001 thousand at the end of 2023[39] - Deferred revenue, current, as of June 30, 2024, was $1,414 thousand, compared to $1,349 thousand at the end of 2023[39] - Inventory balances increased from $15,689 thousand at December 31, 2023, to $17,933 thousand at June 30, 2024, driven by growth in finished goods and raw materials[55] - Total accrued liabilities decreased from $5,717 thousand at December 31, 2023, to $4,262 thousand at June 30, 2024, primarily due to lower compensation accruals[58] Investments and Financial Instruments - Money market funds decreased from $11,171 million as of December 31, 2023, to $5,319 million as of June 30, 2024[51][50] - U.S. treasury bills decreased from $5,942 million as of December 31, 2023, to $2,497 million as of June 30, 2024[51][50] - Warrant derivative liabilities increased from $8,457 million as of December 31, 2023, to $11,885 million as of June 30, 2024[51][50] - The fair value of the Company's financial assets as of June 30, 2024, totaled $12,479 thousand, with unrealized losses of $6 thousand[53] - Total warrant liabilities increased from $8,457 thousand at December 31, 2023, to $11,885 thousand at June 30, 2024, reflecting a change in value of $3,428 thousand[54] Stock-Based Compensation and Equity Plans - Stock-based compensation expense for June 2024 was $1.335 million, down from $3.55 million in June 2023[17] - The Company has reserved a total of 5,550 shares of common stock for issuance under the 2020 Incentive Award Plan as of June 30, 2024[70] - The 2024 Employment Inducement Incentive Award Plan reserves a maximum of 100 shares of common stock for issuance[71] - As of June 30, 2024, the Company had 1,882 stock options outstanding with a weighted average exercise price of $5.22 and a weighted average remaining contractual term of 7.8 years[73] - The total fair value of options vested during the six months ended June 30, 2024 was approximately $1,001[73] - The Company has $1,647 in unrecognized compensation expense related to stock options, to be recognized over a weighted average period of 1.9 years[73] - Total fair value of restricted stock units vested during the three months ended June 30, 2024, was approximately $215, and $494 for the six months ended June 30, 2024[79] - Unrecognized compensation expense related to restricted stock units and performance stock units as of June 30, 2024, was approximately $2,247, expected to be recognized over a weighted-average period of 2.2 years[79] Regulatory and Market Developments - The company's ALLY System received regulatory clearance in India, Taiwan, and other countries, with submissions for certification in South Korea and China[21] - The company expects annual revenue and selling, general, and administrative expenses to increase due to higher ALLY System placements[23] Accounts Receivable and Credit Losses - Accounts receivable allowance for credit losses decreased from $62 million as of December 31, 2023, to $56 million as of June 30, 2024, with a provision change of $(6) million[40] - Notes receivable interest income increased from $20 million in Q2 2023 to $27 million in Q2 2024, and from $32 million in H1 2023 to $56 million in H1 2024[40] - Notes receivable allowance for credit losses decreased from $33 million as of December 31, 2023, to $29 million as of June 30, 2024, with a provision change of $(4) million[41] - No single customer accounted for more than 10% of accounts receivable as of June 30, 2024[143] Contract Assets and Liabilities - Contract assets decreased from $982 million as of December 31, 2023, to $626 million as of June 30, 2024, with $671 million recognized and $(977) million in payments received[42] - Deferred revenue and contract liabilities decreased from $1,919 million as of December 31, 2023, to $1,674 million as of June 30, 2024, with $956 million in billings not yet recognized and $(987) million recognized as revenue[43] - The company expects to recognize $30,805 million in revenue from unsatisfied performance obligations, with $4,415 million expected by December 31, 2024[45] Other Financial Metrics - Transfer from inventories to equipment under lease, net, was $3.367 million in the first six months of 2024, up from $1.281 million in the same period of 2023[18] - The Company allocated $5,605 thousand of the $20,000 thousand gross proceeds from the Private Placement to warrant liabilities[60] - The risk-free interest rate used in the Black-Scholes model for warrant liabilities increased from 3.8% at December 31, 2023, to 4.4% at June 30, 2024[61] - LENSAR has a minimum purchase obligation of approximately $2,242 thousand over the next 15 months under various supply agreements[64] - The Company received $1,368 as a reduction of selling, general and administrative expenses due to the Employee Retention Credit (ERC) in the quarter ended September 30, 2023[65] - The Company sold 20 shares of Series A Redeemable Convertible Preferred Stock for $20,000 in May 2023, which is convertible into 7,940 shares of common stock[67] - Offering costs of $901 were allocated, with $253 to general and administrative expenses and $648 to Series A Redeemable Convertible Preferred Stock[68] - Risk-free interest rate for the three months ended June 30, 2024, ranged from 4.3% to 4.6%, compared to 3.5% to 3.9% in the same period in 2023[75] - Expected volatility for stock-based compensation awards was 59% for the three months ended June 30, 2024, down from 70% in the same period in 2023[75]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39473 LENSAR, INC. (Exact name of registrant as specified in its charter) Delaware 32-0125724 (State or other jurisdiction of i ...

Total Revenue increased 28% and Procedure volume increased 25% over the first quarter of 2023 Increased ALLY ® Adaptive Cataract Treatment System installed base to 65 systems ORLANDO, Fla. (May 9, 2024) – LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2024 and provided an update on key operational initiatives. Exhibit ...

FORM 10-K (Mark One) ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Commission File Number: 001-39473 LENSAR, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organizat ...

Revenue Performance - Total revenue for Q4 2023 was $12.1 million, an increase of 18% compared to $10.2 million in Q4 2022[3] - Full-year revenue for 2023 reached $42.2 million, up 19% from $35.4 million in 2022[8] - Total revenue for Q4 2023 was $12,105,000, representing a 18.3% increase from $10,232,000 in Q4 2022[29] - Product revenue increased to $9,452,000 in Q4 2023, up 21.6% from $7,771,000 in Q4 2022[29] Expenses and Losses - Net loss for Q4 2023 was $3.9 million, or ($0.35) per share, compared to a net loss of $2.5 million, or ($0.24) per share, in Q4 2022[6] - Selling, general and administrative expenses for Q4 2023 were $6.4 million, a decrease of 12% from $7.2 million in Q4 2022[4] - Research and development expenses decreased to $1.5 million in Q4 2023, down 9% from $1.6 million in Q4 2022[5] - Adjusted EBITDA for Q4 2023 was $(1,221,000), compared to $(65,000) in Q4 2022[27] - Net loss for the twelve months ended December 31, 2023, was $(14,383,000), an improvement from $(19,914,000) in 2022[29] - Operating loss for the twelve months ended December 31, 2023, was $(12,229,000), an improvement from $(20,177,000) in 2022[29] - Research and development expenses for the twelve months ended December 31, 2023, were $6,139,000, down from $11,814,000 in 2022[29] - Net loss per common share for the twelve months ended December 31, 2023, was $(1.31), an improvement from $(1.96) in 2022[29] Cash and Assets - Cash and cash equivalents as of December 31, 2023, were $24.6 million, up from $14.7 million at the end of 2022[15] - Cash and cash equivalents increased to $20,621,000 as of December 31, 2023, up from $14,674,000 in 2022[31] - Total assets grew to $69,585,000 in 2023, compared to $55,844,000 in 2022, reflecting a 24.6% increase[31] - Total liabilities increased to $22,409,000 in 2023, compared to $13,860,000 in 2022[31] Operational Highlights - 44 ALLY Adaptive Cataract Treatment Systems were placed in 2023, exceeding the target of 30, with a backlog of 9 systems as of December 31, 2023[1] - Approximately 73% of revenue in Q4 2023 was attributable to recurring sources, compared to 86% in Q4 2022[9] - Procedure volume for 2023 totaled 137,012, a slight increase from 132,113 in 2022, with a 15% increase when excluding South Korea[9][10] Future Outlook - The company expects to secure additional regulatory approvals for the ALLY System in international markets in 2024[2]